Conditional Itpkb disruption in the B cell lineage to avoid anemia and infections, or breeding Itpkb−/− mice into blood cancer models will be required to further explore possible Itpkb tumor-suppressor functions. Here, ITPKB is linked to hematopoietic and lymphoid system neoplasm.